Omada Health Inc

OMDA

Market cap $1.08B

SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore Healthcare Conference, taking place in Miami, including a fireside chat on Wednesday, December 3, 2025, at 1:20 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events . A replay will also be available at the same link following the event.

Pune, India, Nov. 18, 2025 (GLOBE NEWSWIRE) -- QKS Group announced that it has named Omada a Technology Leader and Emerging Innovator in the analysis of the global SPARK MatrixTM: Identity Governance and Administration (IGA), Q4 2025. The QKS Group SPARK Matrix™ includes a detailed analysis of the global market dynamics, major trends, vendor landscape, and competitive positioning. The study provides competitive analysis and ranking of the leading technology vendors in the form of its SPARK MatrixTM. The study offers strategic information for users to evaluate different provider capabilities, competitive differentiation, and market position.

Trump said Thursday that TrumpRx would offer discounts on GLP-1 drugs for weight loss. A few hours later, Omada Health said it will prescribe the drugs starting in 2026.

Omada Health, Inc. ( OMDA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Allan Kells - Vice President of Investor Relations Sean Duffy - Co-Founder, CEO & Director Wei-Li Shao - President Steven Cook - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Craig Hettenbach - Morgan Stanley, Research Division Richard Close - Canaccord Genuity Corp., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Saket Kalia - Barclays Bank PLC, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Gene Mannheimer Presentation Operator Good day, and thank you for standing by. Welcome to the Omada Health Third Quarter 2025 Earnings Conference Call.

The headline numbers for Omada Health, Inc. (OMDA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Revenue of $ 68 million, up 49% ; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarter Highlights Total members of 831,000, up 53% compared with the third quarter of 2024 Revenue of $68 million, up 49% compared with the third quarter of 2024 Prescribing offering: announced plans to launch a new prescribing offering that will combine Omada's evidence-based behavior change program with medication management for anti-obesity medications (AOMs), including GLP-1s; the offering will tailor support before, during, and after treatment–designed to help improve member health outcomes and the value of AOM spend Clinical differentiation: published 30th peer-reviewed manuscript, which demonstrated significant cost savings from Omada's Joint & Muscle Health program, and released data showing that members in the analysis largely maintained their weight one year after discontinuing GLP-1 therapy — an outcome that challenges widespread assumptions of inevitable post-medication weight gain Omada Meal Map: launched Meal Map, an AI-powered nutrition experience that focuses on nutrient quality rather than calorie counting, building on OmadaSpark, the AI-driven nutrition education tool introduced earlier this year “Our third quarter results demonstrate the strength of Omada's multi-product platform in a moment of intense national focus on obesity-related chronic disease,” said Sean Duffy, Co-founder and CEO of Omada Health.

SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. After reporting 53% year-over-year member growth as of the end of Q3, the company is also expanding its offerings.

Virtual care company Omada Health said it will start prescribing GLP-1s and other obesity drugs and help patients manage those medications. The announcement expands the offerings under the company's weight management program as its membership grows to more than 100,000.

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not.

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical Officer. Dr. Tsang brings extensive experience in academia, clinical care delivery, and health information technology.